Literature DB >> 17875548

Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV).

R M Andrade1, G S Alarcón, L A González, M Fernández, M Apte, L M Vilá, G McGwin, J D Reveille.   

Abstract

OBJECTIVE: To examine the predictors of time-to-seizure occurrence and their impact on damage accrual and mortality in LUMINA, a multiethnic (Hispanic, African American and Caucasian) cohort of patients with systemic lupus erythematosus.
METHODS: Seizures were defined as per the American College of Rheumatology (ARC) nomenclature and case definitions for neuropsychiatric lupus syndromes. Factors associated with time-to-seizure occurrence occurring at or after diagnosis (TD) of systemic lupus erythematosus were examined by univariable and multivariable Cox proportional hazard regression analyses. The impact of seizures on damage accrual and mortality was also examined by multivariable analyses after adjusting for variables known to affect these outcomes.
RESULTS: A total of 600 patients were included in these analyses. Of them, 40 (6.7%) developed seizures at or after TD; by multivariable analyses, disease activity and younger age were independent predictors of a shorter time-to-seizure occurrence (HR = 1.10 and 1.04; 95% CI 1.04 to 1.15 and 1.00 to 1.08, p = 0.0004 and 0.0304, respectively) whereas mucocutaneous involvement (HR = 0.34, 95% CI 0.16 to 0.41, p = 0.0039) and hydroxychloroquine use (HR = 0.35, 95% CI 0.15 to 0.80, p = 0.0131) were independent predictors of a longer time-to-seizure occurrence. Seizures were an independent contributor to damage accrual but not to mortality.
CONCLUSIONS: Seizures tend to occur early in the course of systemic lupus erythematosus, and contribute to damage accrual. Younger age and disease activity are independent predictors of a shorter time-to-seizure occurrence; antimalarials appear to have a protective role in seizure occurrence.

Entities:  

Mesh:

Year:  2007        PMID: 17875548      PMCID: PMC2735413          DOI: 10.1136/ard.2007.077594

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  41 in total

1.  Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group.

Authors:  E N Harris
Journal:  Am J Clin Pathol       Date:  1990-10       Impact factor: 2.493

Review 2.  Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome.

Authors:  C Christodoulou; S Sangle; D P D'Cruz
Journal:  Rheumatology (Oxford)       Date:  2007-04-02       Impact factor: 7.580

3.  Epilepsy in systemic lupus erythematosus; effect of cortisone and ACTH.

Authors:  P W RUSSELL; J R HASERICK; E M ZUCKER
Journal:  AMA Arch Intern Med       Date:  1951-07

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy.

Authors:  D Verrot; M San-Marco; C Dravet; P Genton; P Disdier; G Bolla; J R Harle; L Reynaud; P J Weiller
Journal:  Am J Med       Date:  1997-07       Impact factor: 4.965

6.  Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization.

Authors:  Christopher Heeschen; Alexandra Aicher; Ralf Lehmann; Stephan Fichtlscherer; Mariuca Vasa; Carmen Urbich; Christiane Mildner-Rihm; Hans Martin; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

7.  Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture.

Authors:  G S Alarcón; A W Friedman; K V Straaton; J M Moulds; J Lisse; H M Bastian; G McGwin; A A Bartolucci; J M Roseman; J D Reveille
Journal:  Lupus       Date:  1999       Impact factor: 2.911

8.  Epileptic seizures in systemic lupus erythematosus.

Authors:  Simone Appenzeller; Fernando Cendes; Lilian T L Costallat
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

9.  A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE.

Authors:  Mónica Fernández; Graciela S Alarcón; Jaime Calvo-Alén; Rosa Andrade; Gerald McGwin; Luis M Vilá; John D Reveille
Journal:  Arthritis Rheum       Date:  2007-05-15

10.  Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus.

Authors:  E Toubi; M A Khamashta; A Panarra; G R Hughes
Journal:  Am J Med       Date:  1995-10       Impact factor: 4.965

View more
  21 in total

Review 1.  Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  Population-level evidence for an autoimmune etiology of epilepsy.

Authors:  Mei-Sing Ong; Isaac S Kohane; Tianxi Cai; Mark P Gorman; Kenneth D Mandl
Journal:  JAMA Neurol       Date:  2014-05       Impact factor: 18.302

Review 3.  Diabetes and epilepsy in children and adolescents.

Authors:  M Loredana Marcovecchio; Marianna Immacolata Petrosino; Francesco Chiarelli
Journal:  Curr Diab Rep       Date:  2015-04       Impact factor: 4.810

Review 4.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

Review 5.  Neuropsychiatric lupus: new mechanistic insights and future treatment directions.

Authors:  Noa Schwartz; Ariel D Stock; Chaim Putterman
Journal:  Nat Rev Rheumatol       Date:  2019-03       Impact factor: 20.543

6.  Epilepsy associated with systemic autoimmune disorders.

Authors:  Orrin Devinsky; Adam Schein; Souhel Najjar
Journal:  Epilepsy Curr       Date:  2013-03       Impact factor: 7.500

7.  Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.

Authors:  John G Hanly; Murray B Urowitz; Li Su; Caroline Gordon; Sang-Cheol Bae; Jorge Sanchez-Guerrero; Juanita Romero-Diaz; Daniel J Wallace; Ann E Clarke; Em Ginzler; Joan T Merrill; David A Isenberg; Anisur Rahman; M Petri; Paul R Fortin; Dd Gladman; Ian N Bruce; Kristjan Steinsson; Ma Dooley; Munther A Khamashta; Graciela S Alarcón; Barri J Fessler; Rosalind Ramsey-Goldman; Susan Manzi; Asad A Zoma; Gunnar K Sturfelt; Ola Nived; Cynthia Aranow; Meggan Mackay; Manuel Ramos-Casals; Rf van Vollenhoven; Kenneth C Kalunian; Guillermo Ruiz-Irastorza; Sam Lim; Diane L Kamen; Christine A Peschken; Murat Inanc; Chris Theriault; Kara Thompson; Vernon Farewell
Journal:  Ann Rheum Dis       Date:  2012-04-04       Impact factor: 19.103

8.  Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus.

Authors:  J G Hanly; M B Urowitz; L Su; S-C Bae; C Gordon; A Clarke; S Bernatsky; A Vasudevan; D Isenberg; A Rahman; D J Wallace; P R Fortin; D Gladman; J Romero-Diaz; J Romero-Dirz; J Sanchez-Guerrero; M A Dooley; I Bruce; K Steinsson; M Khamashta; S Manzi; R Ramsey-Goldman; G Sturfelt; O Nived; R van Vollenhoven; M Ramos-Casals; C Aranow; M Mackay; K Kalunian; G S Alarcón; B J Fessler; G Ruiz-Irastorza; M Petri; S Lim; D Kamen; C Peschken; V Farewell; K Thompson; C Theriault; J T Merrill
Journal:  Ann Rheum Dis       Date:  2011-10       Impact factor: 19.103

9.  Expression of HMGB1 and TLR4 in neuropsychiatric systemic lupus erythematosus patients with seizure disorders.

Authors:  Qin Huang; Shuqun Shen; Hang Qu; Yu Huang; Danni Wu; Haishan Jiang; Chao Yuan
Journal:  Ann Transl Med       Date:  2020-01

10.  Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients.

Authors:  Eleni I Kampylafka; Haralampos Alexopoulos; Michalis L Kosmidis; Demosthenes B Panagiotakos; Panayiotis G Vlachoyiannopoulos; Marinos C Dalakas; Haralampos M Moutsopoulos; Athanasios G Tzioufas
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.